Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with new...
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial
About this item
Full title
Author / Creator
Herrlinger, Ulrich , Tzaridis, Theophilos , Mack, Frederic , Steinbach, Joachim Peter , Schlegel, Uwe , Sabel, Michael , Hau, Peter , Kortmann, Rolf-Dieter , Krex, Dietmar , Grauer, Oliver , Goldbrunner, Roland , Schnell, Oliver , Bähr, Oliver , Uhl, Martin , Seidel, Clemens , Tabatabai, Ghazaleh , Kowalski, Thomas , Ringel, Florian , Schmidt-Graf, Friederike , Suchorska, Bogdana , Brehmer, Stefanie , Weyerbrock, Astrid , Renovanz, Miriam , Bullinger, Lars , Galldiks, Norbert , Vajkoczy, Peter , Misch, Martin , Vatter, Hartmut , Stuplich, Moritz , Schäfer, Niklas , Kebir, Sied , Weller, Johannes , Schaub, Christina , Stummer, Walter , Tonn, Jörg-Christian , Simon, Matthias , Keil, Vera C , Nelles, Michael , Urbach, Horst , Coenen, Martin , Wick, Wolfgang , Weller, Michael , Fimmers, Rolf , Schmid, Matthias , Hattingen, Elke , Pietsch, Torsten , Coch, Christoph , Glas, Martin and Neurooncology Working Group of the German Cancer Society
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
There is an urgent need for more effective therapies for glioblastoma. Data from a previous unrandomised phase 2 trial suggested that lomustine-temozolomide plus radiotherapy might be superior to temozolomide chemoradiotherapy in newly diagnosed glioblastoma with methylation of the MGMT promoter. In the CeTeG/NOA-09 trial, we aimed to further inves...
Alternative Titles
Full title
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial
Authors, Artists and Contributors
Author / Creator
Tzaridis, Theophilos
Mack, Frederic
Steinbach, Joachim Peter
Schlegel, Uwe
Sabel, Michael
Hau, Peter
Kortmann, Rolf-Dieter
Krex, Dietmar
Grauer, Oliver
Goldbrunner, Roland
Schnell, Oliver
Bähr, Oliver
Uhl, Martin
Seidel, Clemens
Tabatabai, Ghazaleh
Kowalski, Thomas
Ringel, Florian
Schmidt-Graf, Friederike
Suchorska, Bogdana
Brehmer, Stefanie
Weyerbrock, Astrid
Renovanz, Miriam
Bullinger, Lars
Galldiks, Norbert
Vajkoczy, Peter
Misch, Martin
Vatter, Hartmut
Stuplich, Moritz
Schäfer, Niklas
Kebir, Sied
Weller, Johannes
Schaub, Christina
Stummer, Walter
Tonn, Jörg-Christian
Simon, Matthias
Keil, Vera C
Nelles, Michael
Urbach, Horst
Coenen, Martin
Wick, Wolfgang
Weller, Michael
Fimmers, Rolf
Schmid, Matthias
Hattingen, Elke
Pietsch, Torsten
Coch, Christoph
Glas, Martin
Neurooncology Working Group of the German Cancer Society
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2180820094
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2180820094
Other Identifiers
ISSN
0140-6736
E-ISSN
1474-547X
DOI
10.1016/S0140-6736(18)31791-4
